Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lake Success, NY
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Canton, OH
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Middletown, OH
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Nassau,
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Nassau,
Click here to add this to my saved trials
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Petersburg, FL
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy
Evaluation of Skeletal Muscle, Cardiac, and Diaphragm Imaging Biomarkers for GSK2402968 Effects in Ambulatory Boys With Duchenne Muscular Dystrophy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy
Evaluation of Skeletal Muscle, Cardiac, and Diaphragm Imaging Biomarkers for GSK2402968 Effects in Ambulatory Boys With Duchenne Muscular Dystrophy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Grand Rapids, MI
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cullman, AL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cullman, AL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fairfield, CT
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fairfield, CT
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sunrise, FL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sunrise, FL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tampa, FL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Atlanta, GA
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Northbrook, IL
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Northbrook, IL
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Wayne, IN
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Oklahoma City, OK
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Nashville, TN
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Round Rock, TX
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sofia,
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sofia,
Click here to add this to my saved trials
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fullerton, CA
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Janus Ctr. for Psychiatric Research
mi
from
Palm Beach, FL
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Janus Ctr. for Psychiatric Research
mi
from
Palm Beach, FL
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Carman Research
mi
from
Smyrna, GA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Carman Research
mi
from
Smyrna, GA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Adult ADHD Program
mi
from
New York, NY
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Adult ADHD Program
mi
from
New York, NY
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
IPS Research
mi
from
Oklahoma City, OK
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
IPS Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
mi
from
Portland, OR
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Lincoln Research
mi
from
Lincoln, RI
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Lincoln Research
mi
from
Lincoln, RI
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
CNS Healthcare of Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
FutureSearch Clinical Trials
mi
from
Austin, TX
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
FutureSearch Clinical Trials
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Lifetree Clinical Research, LC
mi
from
Salt Lake City, UT
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Lifetree Clinical Research, LC
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
Click here to add this to my saved trials
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Ctr. for Psychiatry & Behavioral Med.
mi
from
Las Vegas, NV
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Ctr. for Psychiatry & Behavioral Med.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)
A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)
Status: Enrolling
Updated:  12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)
A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)
Status: Enrolling
Updated: 12/31/1969
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
GLORIA-AF Registry Program - Second and Third Phases
GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
GLORIA-AF Registry Program - Second and Third Phases
GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials